Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ethyl eicosapentaenoic acid - Mochida Pharmaceutical

Drug Profile

Ethyl eicosapentaenoic acid - Mochida Pharmaceutical

Alternative Names: eicosapentaenoic acid ethyl ester; EPA-E; Epadel; Epadel-T; ethyl icosapentaenoate; ethyl icosapentate; MND-21; MND-2119

Latest Information Update: 05 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mochida Pharmaceutical
  • Developer Mochida Pharmaceutical; Sumitomo Dainippon Pharma
  • Class Antidepressants; Antihyperlipidaemics; Antineoplastics; Antiplatelets; Eicosanoids; Esters; Omega 3 fatty acids; Reactive oxygen species; Small molecules
  • Mechanism of Action Diacylglycerol O acyltransferase inhibitors; Phospholipase A2 inhibitors; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atherosclerosis; Hyperlipidaemia
  • Phase III Hypertriglyceridaemia
  • Discontinued Alzheimer's disease; Chronic heart failure; Non-alcoholic steatohepatitis

Most Recent Events

  • 29 Jun 2019 Mochida Pharmaceutical completes a phase III trial in Hypertriglyceridemia in Japan (NCT03693131)
  • 06 Apr 2019 Mochida terminates Clinical trial in Chronic heart failure in Japan (PO) (UMIN000013609)
  • 08 Feb 2019 Phase-I clinical trials in Hypertriglyceridaemia in China (PO) before February 2019 (Mochida Pharmaceuticals pipeline, March 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top